



Clinical trial results:

A phase III, open-label, multicentre study to evaluate the immunogenicity, safety and reactogenicity study of GSK Biologicals' quadrivalent seasonal influenza candidate vaccine GSK2321138A, administered to children who previously participated in study 115345

Due to a system error, the data reported in v1 is not correct and has been removed from public view.

Summary

| | |
|--------------------------|----------------|
| EudraCT number | 2012-001230-34 |
| Trial protocol | ES CZ GB PL |
| Global end of trial date | 05 June 2013 |

Results information

| | |
|--------------------------------|--|
| Result version number | v2 |
| This version publication date | 28 May 2016 |
| First version publication date | 02 May 2015 |
| Version creation reason | <ul style="list-style-type: none">• Correction of full data set Data correction due to a system error in EudraCT – Results: Secondary endpoint -Serum neutralizing antibody titres against each of the vaccine strains after 1 dose of Fluarix Quadrivalent vaccine. In addition, some data (typos) were corrected in Adverse events section. |

Trial information

Trial identification

| | |
|-----------------------|--------|
| Sponsor protocol code | 116023 |
|-----------------------|--------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT01702454 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | GlaxoSmithKline Biologicals |
| Sponsor organisation address | Rue de l'Institut 89, Rixensart, Belgium, B-1330 |
| Public contact | Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com |
| Scientific contact | Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com |

Notes:

Paediatric regulatory details

| | |
|--|---------------------|
| Is trial part of an agreed paediatric investigation plan (PIP) | Yes |
| EMA paediatric investigation plan number(s) | EMA-000817-PIP02-11 |

| | |
|--|-----|
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | Yes |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 11 December 2013 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 05 June 2013 |
| Global end of trial reached? | Yes |
| Global end of trial date | 05 June 2013 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

To assess the immune response in terms of Haemagglutination Inhibition (HI) antibody titre at Day 7 after one dose of FLU D-QIV vaccine (2012-2013 formulation) in vaccine-primed and vaccine-unprimed subjects, for all strains included in the vaccine.

Protection of trial subjects:

All subjects were supervised closely for at least 30 minutes following vaccination with appropriate medical treatment readily available. Vaccines were administered by qualified and trained personnel. Vaccines/products were administered only to eligible subjects that had no contraindications to any components of the vaccines. Subjects were followed-up from the time the subject consents to participate in the study until she/he is discharged.

Background therapy: -

Evidence for comparator: -

| | |
|---|-----------------|
| Actual start date of recruitment | 06 October 2012 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|---------------------|
| Country: Number of subjects enrolled | Poland: 103 |
| Country: Number of subjects enrolled | Spain: 149 |
| Country: Number of subjects enrolled | United Kingdom: 83 |
| Country: Number of subjects enrolled | Czech Republic: 135 |
| Worldwide total number of subjects | 470 |
| EEA total number of subjects | 470 |

Notes:

Subjects enrolled per age group

| | |
|----------|---|
| In utero | 0 |
|----------|---|

| | |
|---|-----|
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 470 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 0 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms.

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|-----------------------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | Fluarix Quadrivalent Primed Group |

Arm description:

Subjects in this group were previously primed with 2 doses of Fluarix Quadrivalent vaccine in the primary study 115345 (NCT01439360) and received 1 dose of Fluarix Quadrivalent vaccine at Day 0 in the current study. The vaccine was administered intramuscularly in the deltoid region of arm.

| | |
|--|----------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Fluarix Quadrivalent |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Vaccine-primed subjects received a single 0.5 mL dose administered intramuscularly at Visit 1 (Day 0). Vaccines were administered in the deltoid region.

| | |
|------------------|-------------------------------------|
| Arm title | Fluarix Quadrivalent Unprimed Group |
|------------------|-------------------------------------|

Arm description:

Subjects in this group were unprimed in the primary study 115345 (NCT01439360) and received 2 doses of Fluarix Quadrivalent vaccine at Days 0 and 28 in the current study. The vaccine was administered intramuscularly in the deltoid region of arm.

| | |
|--|----------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Fluarix Quadrivalent |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Vaccine-unprimed subjects received one 0.5 mL dose administered intramuscularly at Visit 1 (Day 0) and one 0.5 mL dose administered intramuscularly at Visit 3 (Day 28). Vaccines were administered in the deltoid region.

| Number of subjects in period 1 | Fluarix Quadrivalent Primed Group | Fluarix Quadrivalent Unprimed Group |
|---------------------------------------|--------------------------------------|--|
| Started | 241 | 229 |
| Completed | 238 | 221 |
| Not completed | 3 | 8 |
| Consent withdrawn by subject | - | 1 |
| Lost to Follow-up | 3 | 6 |
| Migrated/moved from study area | - | 1 |

Baseline characteristics

Reporting groups

| | |
|-----------------------|-----------------------------------|
| Reporting group title | Fluarix Quadrivalent Primed Group |
|-----------------------|-----------------------------------|

Reporting group description:

Subjects in this group were previously primed with 2 doses of Fluarix Quadrivalent vaccine in the primary study 115345 (NCT01439360) and received 1 dose of Fluarix Quadrivalent vaccine at Day 0 in the current study. The vaccine was administered intramuscularly in the deltoid region of arm.

| | |
|-----------------------|-------------------------------------|
| Reporting group title | Fluarix Quadrivalent Unprimed Group |
|-----------------------|-------------------------------------|

Reporting group description:

Subjects in this group were unprimed in the primary study 115345 (NCT01439360) and received 2 doses of Fluarix Quadrivalent vaccine at Days 0 and 28 in the current study. The vaccine was administered intramuscularly in the deltoid region of arm.

| Reporting group values | Fluarix Quadrivalent Primed Group | Fluarix Quadrivalent Unprimed Group | Total |
|--|-----------------------------------|-------------------------------------|-------|
| Number of subjects | 241 | 229 | 470 |
| Age categorical Units: Subjects | | | |
| In utero | | | 0 |
| Preterm newborn infants (gestational age < 37 wks) | | | 0 |
| Newborns (0-27 days) | | | 0 |
| Infants and toddlers (28 days-23 months) | | | 0 |
| Children (2-11 years) | | | 0 |
| Adolescents (12-17 years) | | | 0 |
| Adults (18-64 years) | | | 0 |
| From 65-84 years | | | 0 |
| 85 years and over | | | 0 |
| Age continuous Units: years | | | |
| arithmetic mean | 33.2 | 32.5 | |
| standard deviation | ± 7.54 | ± 7.39 | - |
| Gender categorical Units: Subjects | | | |
| Female | 114 | 96 | 210 |
| Male | 127 | 133 | 260 |

End points

End points reporting groups

| | |
|--|-------------------------------------|
| Reporting group title | Fluarix Quadrivalent Primed Group |
| Reporting group description: Subjects in this group were previously primed with 2 doses of Fluarix Quadrivalent vaccine in the primary study 115345 (NCT01439360) and received 1 dose of Fluarix Quadrivalent vaccine at Day 0 in the current study. The vaccine was administered intramuscularly in the deltoid region of arm. | |
| Reporting group title | Fluarix Quadrivalent Unprimed Group |
| Reporting group description: Subjects in this group were unprimed in the primary study 115345 (NCT01439360) and received 2 doses of Fluarix Quadrivalent vaccine at Days 0 and 28 in the current study. The vaccine was administered intramuscularly in the deltoid region of arm. | |

Primary: Serum Hemagglutination Inhibition (HI) antibody titers against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine

| | |
|--|--|
| End point title | Serum Hemagglutination Inhibition (HI) antibody titers against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine |
| End point description: | |
| End point type | Primary |
| End point timeframe: At Day 0 and Day 7 | |

| End point values | Fluarix Quadrivalent Primed Group | Fluarix Quadrivalent Unprimed Group | | |
|--|-----------------------------------|-------------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 224 | 209 | | |
| Units: Titer | | | | |
| geometric mean (confidence interval 95%) | | | | |
| H1N1, Day 0 [N=221,202] | 43.1 (33.8 to 54.9) | 14.5 (11.5 to 18.2) | | |
| H1N1, Day 7 [N=224,209] | 445.6 (376.9 to 526.7) | 45.8 (32 to 65.5) | | |
| H3N2, Day 0 [N=221,202] | 12.3 (10.7 to 14.1) | 16.4 (13.2 to 20.4) | | |
| H3N2, Day 7 [N=224,209] | 135.3 (113.6 to 161.2) | 47.5 (32.6 to 69.3) | | |
| Victoria, Day 0 [N=221,202] | 28.5 (23.8 to 34.1) | 10 (8.4 to 11.9) | | |
| Victoria, Day 7 [N=224,209] | 193.9 (168.7 to 222.8) | 47.1 (35.2 to 63) | | |
| Yamagata, Day 0 [N=221,202] | 11.9 (10.6 to 13.3) | 6.5 (5.9 to 7.2) | | |
| Yamagata, Day 7 [N=224,209] | 182.6 (159 to 209.6) | 26.1 (20.9 to 32.7) | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Adjusted GMT ratio for A/Christ antibodies |
| Comparison groups | Fluarix Quadrivalent Primed Group v Fluarix Quadrivalent Unprimed Group |
| Number of subjects included in analysis | 433 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority |
| Parameter estimate | Adjusted GMT ratio |
| Point estimate | 8.97 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 6.21 |
| upper limit | 12.96 |

| | |
|---|---|
| Statistical analysis title | Adjusted GMT ratio for A/Victoria antibodies |
| Comparison groups | Fluarix Quadrivalent Primed Group v Fluarix Quadrivalent Unprimed Group |
| Number of subjects included in analysis | 433 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority |
| Parameter estimate | Adjusted GMT ratio |
| Point estimate | 2.7 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 1.81 |
| upper limit | 4.02 |

| | |
|---|---|
| Statistical analysis title | Adjusted GMT ratio for B/Brisbane antibodies |
| Comparison groups | Fluarix Quadrivalent Primed Group v Fluarix Quadrivalent Unprimed Group |
| Number of subjects included in analysis | 433 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority |
| Parameter estimate | Adjusted GMT ratio |
| Point estimate | 3.94 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 2.89 |
| upper limit | 5.37 |

| | |
|---|---|
| Statistical analysis title | Adjusted GMT ratio for B/Hub-Wuj antibodies |
| Statistical analysis description: The B/Hub-Wuj = B/Hubei-Wujiagang/158/2009 (Yamagata) strain | |
| Comparison groups | Fluarix Quadrivalent Primed Group v Fluarix Quadrivalent Unprimed Group |
| Number of subjects included in analysis | 433 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority |
| Parameter estimate | Adjusted GMT ratio |
| Point estimate | 6.71 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 5.21 |
| upper limit | 8.63 |

Primary: Number of seropositive subjects against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine

| | |
|--|--|
| End point title | Number of seropositive subjects against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine ^[1] |
| End point description: | |
| End point type | Primary |
| End point timeframe: At Day 0 and Day 7 | |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | Fluarix Quadrivalent Primed Group | Fluarix Quadrivalent Unprimed Group | | |
|-----------------------------|-----------------------------------|-------------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 224 | 209 | | |
| Units: Subjects | | | | |
| H1N1, Day 0 [N=221,202] | 189 | 64 | | |
| H1N1, Day 7 [N=224,209] | 220 | 137 | | |
| H3N2, Day 0 [N=221,202] | 131 | 79 | | |
| H3N2, Day 7 [N=224,209] | 218 | 99 | | |
| Victoria, Day 0 [N=221,202] | 187 | 58 | | |

| | | | | |
|-----------------------------|-----|-----|--|--|
| Victoria, Day 7 [N=224,209] | 224 | 174 | | |
| Yamagata, Day 0 [N=221,202] | 134 | 36 | | |
| Yamagata, Day 7 [N=224,209] | 222 | 144 | | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects seroconverted for HI antibodies against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine.

| | |
|------------------------|---|
| End point title | Number of subjects seroconverted for HI antibodies against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine. |
| End point description: | |
| End point type | Primary |
| End point timeframe: | |
| At Day 7 | |

| End point values | Fluarix Quadrivalent Primed Group | Fluarix Quadrivalent Unprimed Group | | |
|-----------------------------|-----------------------------------|-------------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 221 | 202 | | |
| Units: Subjects | | | | |
| H1N1 | 170 | 65 | | |
| H3N2 | 180 | 73 | | |
| Victoria | 169 | 78 | | |
| Yamagata | 208 | 77 | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Difference in SCR for A/Christ antibodies |
| Statistical analysis description: | |
| To assess the immune response in terms of haemagglutination inhibition (HI) antibody titre at Day 7 after one dose of FLU D-QIV vaccine (2012-2013 formulation) in vaccine-primed and vaccine-unprimed subjects, for all strains included in the vaccine. | |
| Comparison groups | Fluarix Quadrivalent Unprimed Group v Fluarix Quadrivalent Primed Group |

| | |
|---|---------------------------|
| Number of subjects included in analysis | 423 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority |
| Parameter estimate | Difference in percentages |
| Point estimate | 44.74 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 35.87 |
| upper limit | 52.84 |

| | |
|---|---|
| Statistical analysis title | Difference in SCR for A/Victoria antibodies |
| Comparison groups | Fluarix Quadrivalent Primed Group v Fluarix Quadrivalent Unprimed Group |
| Number of subjects included in analysis | 423 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority |
| Parameter estimate | Difference in percentages |
| Point estimate | 45.31 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 36.58 |
| upper limit | 53.3 |

| | |
|---|---|
| Statistical analysis title | Difference in SCR for B/Brisbane antibodies |
| Comparison groups | Fluarix Quadrivalent Primed Group v Fluarix Quadrivalent Unprimed Group |
| Number of subjects included in analysis | 423 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority |
| Parameter estimate | Difference in percentages |
| Point estimate | 37.86 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 28.83 |
| upper limit | 46.26 |

| | |
|--|---|
| Statistical analysis title | Difference in SCR for B/Hu-Wuj antibodies |
| Statistical analysis description: | |
| B/Hu-Wuj = B/Hubei-Wujiagang/158/2009 (Yamagata) | |
| Comparison groups | Fluarix Quadrivalent Primed Group v Fluarix Quadrivalent Unprimed Group |

| | |
|---|---------------------------|
| Number of subjects included in analysis | 423 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority |
| Parameter estimate | Difference in percentages |
| Point estimate | 56 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 48.32 |
| upper limit | 63.04 |

Primary: Mean geometric increase (MGI) for HI antibody titer against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine.

| | |
|-----------------|---|
| End point title | Mean geometric increase (MGI) for HI antibody titer against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine. ^[2] |
|-----------------|---|

End point description:

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

At Day 7

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | Fluarix Quadrivalent Primed Group | Fluarix Quadrivalent Unprimed Group | | |
|--|-----------------------------------|-------------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 221 | 202 | | |
| Units: Fold increase | | | | |
| geometric mean (confidence interval 95%) | | | | |
| H1N1 | 10.3 (8.5 to 12.4) | 3.2 (2.6 to 3.9) | | |
| H3N2 | 10.9 (9.4 to 12.6) | 2.9 (2.4 to 3.6) | | |
| Victoria | 6.7 (5.9 to 7.6) | 4.6 (3.8 to 5.5) | | |
| Yamagata | 15.2 (13.3 to 17.3) | 4 (3.3 to 4.9) | | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects seroprotected for anti-HA antibodies against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine.

| | |
|------------------------|--|
| End point title | Number of subjects seroprotected for anti-HA antibodies against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine. |
| End point description: | |
| End point type | Primary |
| End point timeframe: | |
| At Day 0 and Day 7 | |

| End point values | Fluarix Quadrivalent Primed Group | Fluarix Quadrivalent Unprimed Group | | |
|-----------------------------|-----------------------------------|-------------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 224 | 209 | | |
| Units: Subjects | | | | |
| H1N1, Day 0 [N=221,202] | 89 | 61 | | |
| H1N1, Day 7 [N=224,209] | 217 | 72 | | |
| H3N2, Day 0 [N=221,202] | 37 | 74 | | |
| H3N2, Day 7 [N=224,209] | 193 | 81 | | |
| Victoria, Day 0 [N=221,202] | 72 | 39 | | |
| Victoria, Day 7 [N=224,209] | 217 | 84 | | |
| Yamagata, Day 0 [N=221,202] | 27 | 12 | | |
| Yamagata, Day 7 [N=224,209] | 216 | 83 | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Difference in SPR for A/Christ antibodies |
| Comparison groups | Fluarix Quadrivalent Primed Group v Fluarix Quadrivalent Unprimed Group |
| Number of subjects included in analysis | 433 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority |
| Parameter estimate | Difference in SPR |
| Point estimate | 62.43 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 55.27 |
| upper limit | 68.89 |

| | |
|-----------------------------------|---|
| Statistical analysis title | Difference in SPR for A/Victoria antibodies |
| Comparison groups | Fluarix Quadrivalent Primed Group v Fluarix Quadrivalent Unprimed Group |

| | |
|---|-------------------|
| Number of subjects included in analysis | 433 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority |
| Parameter estimate | Difference in SPR |
| Point estimate | 47.4 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 39.08 |
| upper limit | 55.06 |

| | |
|---|---|
| Statistical analysis title | Difference in SPR for B/Brisbane antibodies |
| Comparison groups | Fluarix Quadrivalent Primed Group v Fluarix Quadrivalent Unprimed Group |
| Number of subjects included in analysis | 433 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority |
| Parameter estimate | Difference in SPR |
| Point estimate | 56.68 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 49.44 |
| upper limit | 63.43 |

| | |
|--|---|
| Statistical analysis title | Difference in SPR for B/Hub-Wuj antibodies |
| Statistical analysis description: The B/Hub-Wuj = B/Hubei-Wujiagang/158/2009 (Yamagata) | |
| Comparison groups | Fluarix Quadrivalent Primed Group v Fluarix Quadrivalent Unprimed Group |
| Number of subjects included in analysis | 433 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority |
| Parameter estimate | Difference in SPR |
| Point estimate | 56.72 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 49.41 |
| upper limit | 63.49 |

Secondary: Number of subjects with HI antibody titers against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent vaccine.

| | |
|-----------------|--|
| End point title | Number of subjects with HI antibody titers against each of the four vaccine strains after 1 dose of Fluarix Quadrivalent |
|-----------------|--|

End point description:

End point type

Secondary

End point timeframe:

At Day 0 and Day 7

| End point values | Fluarix Quadrivalent Primed Group | Fluarix Quadrivalent Unprimed Group | | |
|---|---|--|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 224 | 209 | | |
| Units: Subjects | | | | |
| H1N1 (<1:10), Day 0 [N=221,202] | 32 | 138 | | |
| H1N1 (<1:10), Day 7 [N=224,209] | 4 | 72 | | |
| H3N2 (<1:10), Day 0 [N=221,202] | 90 | 123 | | |
| H3N2 (<1:10), Day 7 [N=224,209] | 6 | 110 | | |
| Victoria (<1:10), Day 0 [N=221,202] | 34 | 144 | | |
| Victoria (<1:10), Day 7 [N=224,209] | 0 | 35 | | |
| Yamagata (<1:10), Day 0 [N=221,202] | 87 | 166 | | |
| Yamagata (<1:10), Day 7 [N=224,209] | 2 | 65 | | |
| H1N1 (1:10 to <1:40), Day 0 [N=221,202] | 100 | 3 | | |
| H1N1 (1:10 to <1:40), Day 7 [N=224,209] | 3 | 65 | | |
| H3N2 (1:10 to <1:40), Day 0 [N=221,202] | 94 | 5 | | |
| H3N2 (1:10 to <1:40), Day 7 [N=224,209] | 25 | 18 | | |
| Victoria (1:10 to <1:40), Day 0 [N=221,202] | 115 | 19 | | |
| Victoria (1:10 to <1:40), Day 7 [N=224,209] | 7 | 90 | | |
| Yamagata (1:10 to <1:40), Day 0 [N=221,202] | 107 | 24 | | |
| Yamagata (1:10 to <1:40), Day 7 [N=224,209] | 6 | 61 | | |
| H1N1 (\geq 1: 40), Day 0 [N=221,202] | 89 | 61 | | |
| H1N1 (\geq 1: 40), Day 7 [N=224,209] | 217 | 72 | | |
| H3N2 (\geq 1: 40), Day 0 [N=221,202] | 37 | 74 | | |
| H3N2 (\geq 1: 40), Day 7 [N=224,209] | 193 | 81 | | |
| Victoria (\geq 1: 40), Day 0 [N=221,202] | 72 | 39 | | |
| Victoria (\geq 1: 40), Day 7 [N=224,209] | 217 | 84 | | |
| Yamagata (\geq 1: 40), Day 0 [N=221,202] | 27 | 12 | | |
| Yamagata (\geq 1: 40), Day 7 [N=224,209] | 216 | 83 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Serum neutralising antibody titers against each of the vaccine strains after 1 dose of Fluarix Quadrivalent vaccine

| | |
|-----------------|---|
| End point title | Serum neutralising antibody titers against each of the vaccine strains after 1 dose of Fluarix Quadrivalent vaccine |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Day 0 and Day 7

| End point values | Fluarix Quadrivalent Primed Group | Fluarix Quadrivalent Unprimed Group | | |
|--|-----------------------------------|-------------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 107 | 109 | | |
| Units: Titer | | | | |
| geometric mean (confidence interval 95%) | | | | |
| H1N1, Day 0 [N=97,90] | 138.2 (97.4 to 196.2) | 48.3 (33.9 to 68.7) | | |
| H1N1, Day 7 [N=107, 96] | 1500.9 (1172.7 to 1920.9) | 139.4 (78.8 to 246.8) | | |
| H3N2, Day 0 [N=99,96] | 66.5 (55.9 to 79.2) | 82.8 (60.6 to 113.1) | | |
| H3N2, Day 7 [N=104,100] | 422.9 (342.3 to 522.4) | 325.1 (187.1 to 564.7) | | |
| Victoria, Day 0 [N=107,109] | 38.6 (29.7 to 50.3) | 22.2 (18.6 to 26.5) | | |
| Victoria, Day 7 [N=107, 108] | 193.7 (154.7 to 242.6) | 47 (30.3 to 72.9) | | |
| Yamagata, Day 0 [N=107,107] | 36.9 (34.2 to 39.8) | 30.8 (29 to 32.6) | | |
| Yamagata, Day 7 [N=107,107] | 182.7 (157.7 to 211.8) | 51.7 (42.2 to 63.4) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Serum anti-neuraminidase antibody titers against each of the vaccine strains after 1 dose of Fluarix Quadrivalent vaccine

| | |
|-----------------|---|
| End point title | Serum anti-neuraminidase antibody titers against each of the vaccine strains after 1 dose of Fluarix Quadrivalent vaccine |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Day 0 and Day 7

| End point values | Fluarix Quadrivalent Primed Group | Fluarix Quadrivalent Unprimed Group | | |
|---|---|--|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 107 | 109 | | |
| Units: Titer | | | | |
| geometric mean (confidence interval 95%) | | | | |
| H1N1, Day 0 [N=106,106] | 34.6 (25.3 to 47.3) | 24.1 (18.6 to 31.1) | | |
| H1N1, Day 7 [N=106, 109] | 293.9 (247.2 to 349.3) | 41.3 (28.9 to 59) | | |
| H3N2, Day 0 [N=107,106] | 38.4 (33.7 to 43.7) | 58.8 (47.2 to 73.4) | | |
| H3N2, Day 7 [N=107, 109] | 189.4 (155.9 to 230.2) | 114.2 (84.1 to 155.2) | | |
| Victoria, Day 0 [N=106,106] | 17.4 (14.2 to 21.3) | 14.3 (12.4 to 16.5) | | |
| Victoria, Day 7 [N=106,109] | 90.6 (74.1 to 110.8) | 27.6 (19.4 to 39.1) | | |
| Yamagata, Day 0 [N=106, 106] | 25.3 (21.6 to 29.6) | 15.4 (13.2 to 18) | | |
| Yamagata, Day 7 [N=106,109] | 222 (185.7 to 265.4) | 40.6 (29.5 to 55.7) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Vaccine response rate (VRR) for neutralising antibody titers against each of the four vaccine strains.

| | |
|-----------------|--|
| End point title | Vaccine response rate (VRR) for neutralising antibody titers against each of the four vaccine strains. |
|-----------------|--|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Day 7 post dose 1

| End point values | Fluarix Quadrivalent Primed Group | Fluarix Quadrivalent Unprimed Group | | |
|-----------------------------|---|--|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 107 | 108 | | |
| Units: Subjects | | | | |
| H1N1 [N=97,89] | 74 | 36 | | |
| H3N2 [N=97,94] | 72 | 48 | | |
| Victoria [N=107,108] | 78 | 24 | | |
| Yamagata [N=107,105] | 45 | 15 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: VRR for anti-neuraminidase antibody titers against each of the four vaccine strains.

| | |
|-----------------|--|
| End point title | VRR for anti-neuraminidase antibody titers against each of the four vaccine strains. |
|-----------------|--|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Day 7 post dose 1

| End point values | Fluarix Quadrivalent Primed Group | Fluarix Quadrivalent Unprimed Group | | |
|-----------------------------|---|--|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 107 | 106 | | |
| Units: Subjects | | | | |
| H1N1 [N=105,106] | 75 | 31 | | |
| H3N2 [N=107,106] | 75 | 31 | | |
| Victoria [N=105,106] | 79 | 24 | | |
| Yamagata [N=105,106] | 90 | 29 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: MGI for neutralising antibodies titres against each of the four vaccine strains.

| | |
|-----------------|--|
| End point title | MGI for neutralising antibodies titres against each of the four vaccine strains. |
|-----------------|--|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Day 7

| End point values | Fluarix Quadrivalent Primed Group | Fluarix Quadrivalent Unprimed Group | | |
|---|---|--|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 107 | 108 | | |
| Units: Fold increase | | | | |
| geometric mean (confidence interval 95%) | | | | |
| H1N1 [N=97, 89] | 10.6 (8.2 to 13.7) | 3.1 (2.3 to 4.2) | | |
| H3N2 [N=97, 94] | 6.4 (5.4 to 7.6) | 4.5 (3.2 to 6.2) | | |
| Victoria [N=107,108] | 5 (4.3 to 5.8) | 2.1 (1.6 to 2.8) | | |
| Yamagata [N=107,105] | 5 (4.3 to 5.7) | 1.7 (1.4 to 2) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: MGI for anti-neuraminidase antibodies titers against each of the four vaccine strains.

| | |
|-----------------|--|
| End point title | MGI for anti-neuraminidase antibodies titers against each of the four vaccine strains. |
|-----------------|--|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Day 7 post dose 1

| End point values | Fluarix Quadrivalent Primed Group | Fluarix Quadrivalent Unprimed Group | | |
|---|---|--|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 107 | 106 | | |
| Units: Fold increase | | | | |
| geometric mean (confidence interval 95%) | | | | |
| H1N1 [N=105,106] | 8.3 (6.5 to 10.7) | 1.8 (1.5 to 2.1) | | |
| H3N2 [N=105,106] | 5.2 (4.4 to 6) | 1.9 (1.5 to 2.4) | | |

| | | | | |
|----------------------|-------------------|------------------|--|--|
| Victoria [N=105,106] | 8.8 (7.5 to 10.2) | 2.7 (2.1 to 3.4) | | |
| Yamagata [N=107,106] | 4.9 (4.2 to 5.8) | 2 (1.7 to 2.3) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any and grade 3 solicited local adverse events (AEs)

| | |
|-----------------|---|
| End point title | Number of subjects reporting any and grade 3 solicited local adverse events (AEs) |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

During a 7-day (Day 0 to 6) follow-up period after first vaccination

| End point values | Fluarix Quadrivalent Primed Group | Fluarix Quadrivalent Unprimed Group | | |
|-----------------------------|---|--|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 239 | 228 | | |
| Units: Subjects | | | | |
| Any Pain | 96 | 61 | | |
| Grade 3 Pain | 2 | 1 | | |
| Any Redness | 82 | 48 | | |
| Grade 3 Redness | 2 | 0 | | |
| Any Swelling | 49 | 25 | | |
| Grade 3 Swelling | 2 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of solicited symptoms

| | |
|-----------------|--------------------------------|
| End point title | Duration of solicited symptoms |
|-----------------|--------------------------------|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

During the 7-day (Days 0-6) post-vaccination Dose 1 period

| End point values | Fluarix Quadrivalent Primed Group | Fluarix Quadrivalent Unprimed Group | | |
|-------------------------------|---|--|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 96 | 61 | | |
| Units: Days | | | | |
| median (full range (min-max)) | | | | |
| Drowsiness | 1 (1 to 7) | 1 (1 to 4) | | |
| Irritability/fussiness | 2 (1 to 7) | 2 (1 to 7) | | |
| Loss of appetite | 2 (1 to 7) | 2 (1 to 5) | | |
| Pain | 1 (1 to 5) | 1 (1 to 5) | | |
| Redness | 2 (1 to 7) | 2 (1 to 6) | | |
| Swelling | 2 (1 to 5) | 1 (1 to 5) | | |
| Temperature | 1 (1 to 5) | 2 (1 to 6) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any, grade 3 and related solicited general symptoms.

| | |
|-----------------|---|
| End point title | Number of subjects reporting any, grade 3 and related solicited general symptoms. |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

During the 7 days (Days 0 – 6) post dose 1 vaccination

| End point values | Fluarix Quadrivalent Primed Group | Fluarix Quadrivalent Unprimed Group | | |
|--------------------------------|---|--|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 238 | 224 | | |
| Units: Subjects | | | | |
| Any Drowsiness | 54 | 44 | | |
| Grade 3 Drowsiness | 5 | 1 | | |
| Related Drowsiness | 36 | 28 | | |
| Any Irritability/Fussiness | 77 | 59 | | |
| Grade 3 Irritability/Fussiness | 5 | 5 | | |
| Related Irritability/Fussiness | 51 | 43 | | |
| Any Loss of appetite | 51 | 46 | | |
| Grade 3 Loss of appetite | 8 | 5 | | |

| | | | | |
|--------------------------|----|----|--|--|
| Related Loss of appetite | 31 | 31 | | |
| Any Temperature | 13 | 26 | | |
| Grade 3 Temperature | 2 | 1 | | |
| Related Temperature | 6 | 15 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting AEs with Medically Attended Visits (MAV)

| | |
|-----------------|---|
| End point title | Number of subjects reporting AEs with Medically Attended Visits (MAV) |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

During the entire study period (Day 0 – Day 179)

| End point values | Fluarix Quadrivalent Primed Group | Fluarix Quadrivalent Unprimed Group | | |
|-----------------------------|---|--|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 241 | 229 | | |
| Units: Subjects | | | | |
| Any MAV | 149 | 130 | | |
| Grade 3 MAV | 5 | 8 | | |
| Related MAV | 0 | 1 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting Potential Immune-Mediated Diseases (pIMDs)

| | |
|-----------------|---|
| End point title | Number of subjects reporting Potential Immune-Mediated Diseases (pIMDs) |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

During the entire study period (Days 0 - 179)

| End point values | Fluarix Quadrivalent Primed Group | Fluarix Quadrivalent Unprimed Group | | |
|-----------------------------|---|--|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 241 | 229 | | |
| Units: Subjects | | | | |
| Any pIMD | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any, grade 3 and related unsolicited AEs.

| | |
|-----------------|--|
| End point title | Number of subjects reporting any, grade 3 and related unsolicited AEs. |
|-----------------|--|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Within 28 days (Days 0-27) after first vaccination

| End point values | Fluarix Quadrivalent Primed Group | Fluarix Quadrivalent Unprimed Group | | |
|-----------------------------|---|--|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 241 | 229 | | |
| Units: Subject | | | | |
| Any Unsolicited AEs | 66 | 66 | | |
| Grade 3 Unsolicited AEs | 6 | 7 | | |
| Related Unsolicited AEs | 5 | 3 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any and related serious adverse events (SAEs)

| | |
|-----------------|--|
| End point title | Number of subjects reporting any and related serious adverse events (SAEs) |
|-----------------|--|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

During the entire study period (Day 0 – Day 179)

| End point values | Fluarix Quadrivalent Primed Group | Fluarix Quadrivalent Unprimed Group | | |
|-----------------------------|---|--|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 241 | 229 | | |
| Units: Subjects | | | | |
| Any SAE(s) | 7 | 8 | | |
| Related SAE(s) | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Serious Adverse Events: From Day 0 to Day 179; Solicited local and general symptoms: During the 7-day (Days 0-6) post-vaccination period; Unsolicited symptoms: During the 28-day (Day 0-27) post-vaccination period.

Adverse event reporting additional description:

For the frequent adverse events, the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.

| | |
|-----------------|----------------|
| Assessment type | Non-systematic |
|-----------------|----------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 16.1 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|-------------------------------------|
| Reporting group title | Fluarix Quadrivalent Unprimed Group |
|-----------------------|-------------------------------------|

Reporting group description:

Subjects in this group were unprimed in the primary study 115345 (NCT01439360) and received 2 doses of Fluarix Quadrivalent vaccine at Days 0 and 28 in the current study. The vaccine was administered intramuscularly in the deltoid region of arm.

| | |
|-----------------------|-----------------------------------|
| Reporting group title | Fluarix Quadrivalent Primed Group |
|-----------------------|-----------------------------------|

Reporting group description:

Subjects in this group were previously primed with 2 doses of Fluarix Quadrivalent vaccine in the primary study 115345 (NCT01439360) and received 1 dose of Fluarix Quadrivalent vaccine at Day 0 in the current study. The vaccine was administered intramuscularly in the deltoid region of arm.

| Serious adverse events | Fluarix Quadrivalent Unprimed Group | Fluarix Quadrivalent Primed Group | |
|---|-------------------------------------|-----------------------------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 8 / 229 (3.49%) | 7 / 241 (2.90%) | |
| number of deaths (all causes) | 0 | 0 | |
| number of deaths resulting from adverse events | 0 | 0 | |
| Injury, poisoning and procedural complications | | | |
| Thermal burn | | | |
| subjects affected / exposed | 0 / 229 (0.00%) | 1 / 241 (0.41%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal disorders | | | |
| Inguinal hernia | | | |
| subjects affected / exposed | 1 / 229 (0.44%) | 0 / 241 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |

| | | | |
|---|-----------------|-----------------|--|
| Adenoidal hypertrophy | | | |
| subjects affected / exposed | 1 / 229 (0.44%) | 0 / 241 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Upper respiratory tract inflammation | | | |
| subjects affected / exposed | 0 / 229 (0.00%) | 1 / 241 (0.41%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Skin and subcutaneous tissue disorders | | | |
| Urticaria | | | |
| subjects affected / exposed | 0 / 229 (0.00%) | 1 / 241 (0.41%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 0 / 229 (0.00%) | 1 / 241 (0.41%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| Gastroenteritis | | | |
| subjects affected / exposed | 2 / 229 (0.87%) | 0 / 241 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bronchiolitis | | | |
| subjects affected / exposed | 1 / 229 (0.44%) | 0 / 241 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 229 (0.00%) | 1 / 241 (0.41%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bronchopneumonia | | | |

| | | | |
|---|-----------------|-----------------|--|
| subjects affected / exposed | 0 / 229 (0.00%) | 1 / 241 (0.41%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Laryngitis | | | |
| subjects affected / exposed | 0 / 229 (0.00%) | 1 / 241 (0.41%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lymphadenitis bacterial | | | |
| subjects affected / exposed | 1 / 229 (0.44%) | 0 / 241 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Otitis media | | | |
| subjects affected / exposed | 0 / 229 (0.00%) | 1 / 241 (0.41%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Otitis media acute | | | |
| subjects affected / exposed | 0 / 229 (0.00%) | 1 / 241 (0.41%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pharyngitis | | | |
| subjects affected / exposed | 1 / 229 (0.44%) | 0 / 241 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia bacterial | | | |
| subjects affected / exposed | 1 / 229 (0.44%) | 0 / 241 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rhinitis | | | |
| subjects affected / exposed | 0 / 229 (0.00%) | 1 / 241 (0.41%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sinusitis | | | |

| | | | |
|---|-----------------|-----------------|--|
| subjects affected / exposed | 0 / 229 (0.00%) | 1 / 241 (0.41%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Fluarix Quadrivalent Unprimed Group | Fluarix Quadrivalent Primed Group | |
|---|--|--------------------------------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 61 / 229 (26.64%) | 96 / 241 (39.83%) | |
| General disorders and administration site conditions | | | |
| Pain | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed ^[1] | 61 / 228 (26.75%) | 96 / 239 (40.17%) | |
| occurrences (all) | 61 | 96 | |
| Redness | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed ^[2] | 48 / 228 (21.05%) | 82 / 239 (34.31%) | |
| occurrences (all) | 48 | 82 | |
| Swelling | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed ^[3] | 25 / 228 (10.96%) | 49 / 239 (20.50%) | |
| occurrences (all) | 25 | 49 | |
| Drowsiness | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed ^[4] | 44 / 224 (19.64%) | 54 / 238 (22.69%) | |
| occurrences (all) | 44 | 54 | |
| Irritability/Fussiness | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed ^[5] | 59 / 224 (26.34%) | 77 / 238 (32.35%) | |
| occurrences (all) | 59 | 77 | |
| Loss of Appetite | | | |
| subjects affected / exposed ^[6] | 46 / 224 (20.54%) | 51 / 238 (21.43%) | |
| occurrences (all) | 46 | 51 | |
| Temperature | | | |

| | | | |
|---|-------------------------|------------------------|--|
| alternative assessment type: Systematic subjects affected / exposed ^[7] occurrences (all) | 26 / 224 (11.61%) 26 | 13 / 238 (5.46%) 13 | |
| Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all) | 13 / 229 (5.68%) 13 | 9 / 241 (3.73%) 9 | |

Notes:

[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.

[2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.

[3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.

[4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.

[5] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.

[6] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.

[7] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported